PeptideStack
5.2kquestions
20kanswers
220users

How many vials from a QSC lot should I send for identity confirmation by mass spectrometry?

Asked 31 Mar 2025Modified 13 months agoViewed 38k times
34

Details up front: QSC · identity confirmation by mass spectrometry.

I have worked this out and I would like someone to find the error, because I suspect there is one.

My working so far, for the record, is below, and I am fairly sure the error is in the unit conversion rather than the algebra.

Where is my error, and what is the correct working?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
cost-analysis
cost-analysis

Cost arithmetic done honestly: cost per milligram after dead-space loss, list versus net price, comparing a multi-dose vial to a fixed-dose pen,…

260 questions
mass-spec
mass-spec

Mass spectrometry for identity confirmation: electrospray ionisation, multiple charge states, monoisotopic versus average mass, deconvolution, and…

52 questions
shareeditfollowflag
SH
askedseven_day_half31k13831 Mar 2025
7Same situation here, so I will follow this one. – Dr_Nadia_Farsi 2 months ago
8Can you say which laboratory and which method? The answer changes with both. – ten_mg_vial 4 months ago
add a comment

5 Answers

Accepted answer first, then by votes
135

Accepted answer

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

Put another way, acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
SB
answered · accepteds_bhattacharya31k3813 May 2025
6Do you have the chromatogram for this, or just the summary figure? – tenth_of_a_unit 4 months ago
7Adding for future readers: the certificate should carry the lot number, not just a batch code. – Dr_Hanne_Solberg 6 months ago
add a comment
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
53

The failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

In practice, if you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
NN
answerednine_point_nine60k14824 May 2025
Two of us submitted the same lot to different laboratories and got results a tenth apart. – dead_volume 3 months ago
add a comment
42

The single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

The underlying point is that stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

Assume segregation is possible, and design your sampling to catch it if it exists.

edited 26 Jun 2025 by j_wierzbicki — added the method parameters

shareimprove this answerflag
JW
answeredj_wierzbicki69k1484 Jun 2025
This should be linked from the help pages. – greta_holzmann 4 months ago
2For what it is worth, my own independent result was within half a per cent of this. – micron22 6 months ago
add a comment
33

The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

edited 26 Jun 2025 by dead_volume — reworded for clarity after a comment

shareimprove this answerflag
DV
answereddead_volume56k4816 Jun 2025
26

The relevant detail is that if a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.

Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

edited 12 Jul 2025 by e_dziedzic — added the citation requested in comments

shareimprove this answerflag
ED
answerede_dziedzic51k14727 Jun 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.